Literature DB >> 17505009

Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.

Brad J Stish1, Hua Chen, Yanqun Shu, Angela Panoskaltsis-Mortari, Daniel A Vallera.   

Abstract

PURPOSE: erbB2, the product of the Her2-neu gene, is a well-established therapeutic target for antibody-based biologicals, but anti-erbB2 antibody-toxin fusion proteins are limited in their activity. The goal of this study was to determine if genetically adding an sFv targeting epithelial cell adhesion molecule (EpCAM) to an anti-Her2 sFv immunotoxin would result in enhanced antitumor activity. EXPERIMENTAL
DESIGN: In vitro studies were done in which the new bispecific immunotoxin DTEpCAM23 was compared with monospecific immunotoxins (DTEpCAM and DT23) to quantitate immunotoxin activity. Mixtures of monospecific immunotoxins were tested to determine if they were as effective as the bispecific immunotoxin. Binding and internalization studies were also done. In vivo, bispecific immunotoxins were given i.t. to athymic nude mice bearing HT-29 human colon cancer flank tumors and i.p. to mice with i.p. tumors.
RESULTS: DTEpCAM23 bispecific immunotoxins showed far greater activity than monospecific immunotoxin (sometimes over 2,000-fold) against most tumor lines. Bispecific immunotoxin was superior and selective in its activity against different carcinoma cell lines. Bispecific immunotoxin had greater activity than monospecific immunotoxin indicating an advantage of having both sFv on the same single-chain molecule. Binding and internalization studies did not explain the differences between bispecific immunotoxin and monospecific immunotoxin activity. Orientation of the sFvs on the molecule had a significant effect on in vitro and in vivo properties. The bispecific immunotoxins were more effective than the monospecific immunotoxin in the flank tumor mouse model.
CONCLUSIONS: The synthesis of bispecific immunotoxin created a new biological agent with superior in vitro and in vivo activity (over monospecific immunotoxin), more broad reactivity, more efficacy against tumors in vivo, and diminished toxic effects in mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505009     DOI: 10.1158/1078-0432.CCR-06-2454

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.

Authors:  Alessandra Villa; Valeria Lovato; Emil Bujak; Sarah Wulhfard; Nadine Pasche; Dario Neri
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

3.  A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.

Authors:  Seunguk Oh; Brad J Stish; Selwyn M Vickers; Donald J Buchsbaum; Ashok K Saluja; Daniel A Vallera
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

4.  A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

Authors:  Nate N Waldron; Sanford H Barsky; Phillip R Dougherty; Daniel A Vallera
Journal:  Target Oncol       Date:  2013-07-31       Impact factor: 4.493

5.  Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.

Authors:  Seunguk Oh; John R Ohlfest; Deborah A Todhunter; Vincent D Vallera; Walter A Hall; Hua Chen; Daniel A Vallera
Journal:  J Neurooncol       Date:  2009-06-11       Impact factor: 4.130

6.  A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.

Authors:  Seunguk Oh; Brad J Stish; Deepali Sachdev; Hua Chen; Arkadiusz Z Dudek; Daniel A Vallera
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

7.  Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

Authors:  Daniel A Vallera; Bin Zhang; Michelle K Gleason; Seunguk Oh; Louis M Weiner; Dan S Kaufman; Valarie McCullar; Jeffrey S Miller; Michael R Verneris
Journal:  Cancer Biother Radiopharm       Date:  2013-04-23       Impact factor: 3.099

8.  Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.

Authors:  Daniel A Vallera; Hua Chen; Andrew R Sicheneder; Angela Panoskaltsis-Mortari; Elizabeth P Taras
Journal:  Leuk Res       Date:  2009-03-26       Impact factor: 3.156

9.  Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.

Authors:  D A Vallera; B J Stish; Y Shu; H Chen; A Saluja; D J Buchsbaum; S M Vickers
Journal:  Gut       Date:  2008-01-25       Impact factor: 23.059

10.  Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Authors:  B J Stish; S Oh; H Chen; A Z Dudek; R A Kratzke; D A Vallera
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.